Codiak BioSciences, Inc. Common Stock
CDAK
CDAK was delisted on the 4th of April, 2023.
48 hedge funds and large institutions have $13.6M invested in Codiak BioSciences, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 12 closing their positions.
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
2% less funds holding
Funds holding: 49 → 48 (-1)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
60% less capital invested
Capital invested by funds: $33.6M → $13.6M (-$20M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$3.57M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.32M |
| 3 |
AC
Armistice Capital
New York
|
+$2.1M |
| 4 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
+$2.06M |
| 5 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.34M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$950K |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$760K |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$186K |
| 5 |
E
Ergoteles
New York
|
-$73.4K |
CDAK Hedge Fund Activity: Q3 2022 in Review
48 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q3 2022, worth a combined $13.6M — down 60% from $33.6M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CDAK and 11 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 12 added.
The largest buyer was Laurion Capital Management, adding an estimated $3.57M. The largest seller was Oracle Investment Management, exiting entirely with an estimated $1.34M sold.
- 48 institutional investors held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q3 2022, down from 49 in Q2 2022.
- Funds reported $13.6M of Codiak BioSciences, Inc. Common Stock stock for Q3 2022, down 60% quarter-over-quarter.
- 11 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q3 2022 and 12 closed out, a net change of -1 holder.
- The largest Codiak BioSciences, Inc. Common Stock buyer in Q3 2022 was Laurion Capital Management, an estimated $3.57M added.
- The largest Codiak BioSciences, Inc. Common Stock seller in Q3 2022 was Oracle Investment Management, an estimated $1.34M sold.
Based on aggregated 13F filings for Q3 2022.